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Background: Ezetimibe ameliorates serum low-density lipoprotein cholesterol (LDL-c) and it has been approved for
the treatment of hypercholesterolemia. However, the effects of ezetimibe on specific biomarkers have not been fully
clarified in obese Japanese patients.
Methods: A total of 101 patients (47 males and 54 females) were registered in this study during 2011 and 2012. All
patients were over 20 years old, were obese [body mass index (BMI) ≥ 25kg/m2] and had hypercholesterolemia
(LDL-c ≥ 120mg/dl). After excluding 10 subjects (7 who dropped out and 3 with missing data), 91 patients (39
males and 52 females) were analyzed. They were treated with 10 mg ezetimibe once a day for 24 weeks and were
evaluated at 12 and 24 weeks.
Results: Following 12 weeks of ezetimibe therapy, BMI (p < 0.001), waist circumference (p < 0.001), total cholesterol
(p < 0.001), LDL-c (p < 0.001), non high-density lipoprotein cholesterol [HDL-c] (p < 0.001), triglycerides (p < 0.05) and
remnant-like particle cholesterol (RLP-c; p < 0.001) were significantly decreased. Following 24 weeks of ezetimibe
therapy, BMI (p < 0.05), waist circumference (p < 0.001), total cholesterol (p < 0.001), LDL-c (p < 0.001), non HDL-c
(p < 0.001), triglycerides (p < 0.05), RLP-c (p < 0.001), insulin (p < 0.05) and hepatocyte growth factor (HGF; p < 0.05)
were significantly decreased. In contrast, HDL-c (p < 0.001) was significantly increased.
Conclusions: Ezetimibe ameliorated not only atherogenic lipid profiles but also anthropometric factors, insulin
resistance and biomarkers such as HGF. Ezetimibe may have pleiotropic effects on obese patients with
hypercholesterolemia.
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Ezetimibe is a novel lipid-lowering agent that inhibits in-
testinal absorption of dietary and biliary cholesterol. The
effects of ezetimibe on low-density lipoprotein cholesterol
(LDL-c), as well as on baseline lipid profile, hypertension,
diabetes mellitus and body mass index (BMI) were found
to be generally consistent across all subgroups analyzed
[1]. Numerous clinical studies [2-10] have revealed that
combination therapy with ezetimibe is beneficial in redu-
cing LDL-c, remnant-like particle cholesterol (RLP-c), and* Correspondence: hadac@med.kurume-u.ac.jp
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unless otherwise stated.triglycerides, and in increasing high-density lipoprotein
cholesterol (HDL-c) in patients with metabolic syndrome
(MetS) or diabetes. Ezetimibe may have more effect in pa-
tients with MetS than in non-obese subjects [11]. We and
others clarified that the values of RLP-c, aldosterone and
hepatocyte growth factor (HGF) were elevated in patients
with MetS [12-17]. Moreover, the levels of adiponectine
and the ratio of eicosapentaenoic acid to arachidonic acid
(EPA/AA) were decreased in patients with MetS [18-20].
The purpose of the present study was to investigate
whether the levels of such biomarkers were improved by
ezetimibe either in monotherapy or combined therapy in
Japanese obese subjects [21].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Table 1 shows the characteristics of the 101 subjects (47
males and 54 females). The mean age of the subjects was
56.7 ± 11.3 years in males and 63.1 ± 11.6 years in females.
The mean BMI was 27.7 ± 3.6kg/m2 in males and 27.6 ±
3.4kg/m2 in females. The mean waist circumference was
94.6 ± 10.4cm in males and 95.7 ± 8.1cm in females. As
apparent from Table 1, the prevalence of metabolic
syndrome-related factors was high. The mean height (p <






Age (years) 56.7 ± 11.3 63.1 ± 11.6 0.008
Height (cm) 166.9 ± 5.9 152.9 ± 8.0 <0.001
Weight (kg) 77.3 ± 12.7 64.6 ± 10.1 <0.001
Body mass
index (kg/m2)
27.7 ± 3.6 27.6 ± 3.4 0.919
Waist circumference
(cm)
94.6 ± 10.4 95.7 ± 8.1 0.622
Systolic blood
pressure (mmHg)
129.1 ± 14.3 127.9 ± 15.4 0.705
Diastolic blood
pressure (mmHg)
77.1 ± 8.5 74.7 ± 10.4 0.229
Total cholesterol
(mg/dl)
223.3 ± 32.6 243.6.1 ± 35.1 0.003
LDL-cholesterol
(mg/dl)
138.7 ± 26.9 152.2 ± 29.7 0.020
HDL-cholesterol
(mg/dl)
48.8 ± 10.1 53.6 ± 10.7 0.024
Non HDL-
cholesterol (mg/dl)
174.5 ± 29.8 190.1 ± 31.1 0.012
Triglycerides*
(mg/dl)
172.4 (56–1804) 151.4 (62–473) 0.214
RLP-cholesterol*
(mg/dl)
6.7 (2.2-82.5) 6.5 (2.4-28.7) 0.868
Free fatty acid*
(mEq/l)
428.3 (92–1423) 437.0 (87–1134) 0.834
Plasma glucose
(mg/dl)
108.5 ± 26.7 103.4 ± 29.1 0.360
Insulin* (μU/ml) 12.9 (1.55-200) 10.2 (2.82-72.6) 0.180
HOMA index* 3.36 (0.35-80.5) 2.51 (0.64-36.2) 0.146
hs CRP* (mg/dl) 720.5 (50-19100) 713.4 (50-7910) 0.990
Aldosterone
(pg/dl)*
95.6 (42.2-315.0) 85.6 (37.9-296.0) 0.238
HGF (ng/ml) 0.32 ± 0.05 0.31 ± 0.06 0.731
Adiponectine
(μg/ml)*
1.97 (0.28-10.6) 3.21 (0.30-8.34) 0.001
EPA/AA* 0.35 (0.10-2.05) 0.30 (0.10-1.59) 0.226
Data are means (SD), geometric mean and range. *: These variables are shown
in the original scale after analysis using log (natural)-transformed values.
Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model
assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to
arachidonic acid.males than in females. The mean age (p < 0.01), total chol-
esterol (p < 0.01), LDL-c (p < 0.05), HDL-c (p < 0.05), non
HDL-c (p < 0.05) and adiponectine (p < 0.01) were signifi-
cantly lower in males than in females.
Table 2 shows the anthropometric and laboratory data
before, at 12 weeks, and at 24 weeks after ezetimibe treat-
ments. Following 12 weeks of ezetimibe therapy, BMI (p <
0.001), waist circumference (p < 0.001), total cholesterol
(p < 0.001), LDL-c (p < 0.001), non HDL-c (p < 0.001), tri-
glycerides (p < 0.05) and RLP-c (p < 0.001) were signifi-
cantly decreased. Following 24 weeks of ezetimibe
therapy, BMI (p < 0.05), waist circumference (p < 0.001),
total cholesterol (p < 0.001), LDL-c (p < 0.001), non HDL-c
(p < 0.001), triglycerides (p < 0.05), RLP-c (p < 0.001), insu-
lin (p < 0.05) and HGF (p < 0.05) were significantly de-
creased. In contrast, HDL-c (p < 0.001) was significantly
increased. There were no significant changes in systolicTable 2 Lipids and other biomarkers at baseline and at 3
and 6 months after the ezetimibe therapy
Parameters Pre Post 3M Post 6M
Body mass index
(kg/m2)
27.9 ± 3.5 27.5 ± 3.4*** 27.6 ± 3.4*
Waist circumference
(cm)
93.6 ± 8.5 91.8 ± 7.8*** 91.5 ± 7.9***
Systolic blood
pressure (mmHg)
128.7 ± 14.8 127.2 ± 13.9 127.0 ± 13.0
Diastolic blood
pressure (mmHg)
76.0 ± 9.4 75.6 ± 9.4 74.4 ± 10.3
Total cholesterol
(mg/dl)
236.2 ± 34.7 208.9 ± 31.9*** 207.0 ± 34.5***
LDL-cholesterol
(mg/dl)
147.9 ± 29.5 125.5 ± 25.9*** 126.5 ± 30.5***
HDL-cholesterol
(mg/dl)
51.7 ± 10.7 52.7 ± 10.3 54.5 ± 9.8***
Non HDL-cholesterol
(mg/dl)
184.5 ± 30.7 156.2 ± 29.1*** 151.9 ± 32.6***
Triglycerides+ (mg/dl) 162.4 145.5* 134.3***
RLP-cholesterol+ (mg/dl) 6.6 5.2*** 4.7***
Free fatty acid+ (mEq/l) 437.0 454.8 483.0
Plasma glucose (mg/dl) 106.4 ± 28.8 107.3 ± 24.5 103.3 ± 24.1
Insulin+ (μU/ml) 11.9 11.1 10.0*
HOMA index+ 3.1 2.8 2.6
hsCRP+ (mg/dl) 765.1 820.6 871.3
Aldosterone (pg/dl)+ 90.9 97.5 96.5
HGF (ng/ml) 0.32 ± 0.06 0.31 ± 0.04 0.30 ± 0.03*
Adiponectine (μg/ml)+ 2.58 2.64 2.53
EPA/AA+ 0.31 0.31 0.31
*: p < 0.05, ***: p < 0.001.
Data are means (SD), geometric mean and range. *: These variables are shown
in the original scale after analysis using log (natural)-transformed values.
Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model
assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to
arachidonic acid.
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plasma glucose, homeostasis model assessment (HOMA)
index, high sensitive CRP (hsCRP), aldosterone, adiponec-
tine or EPA/AA.
Table 3 shows the anthropometric and laboratory data
before and at 24 weeks after ezetimibe monotherapy or
combined therapy. Following 24 weeks of ezetimibe
monotherapy, BMI (p < 0.05), waist circumference (p <
0.001), systolic (p < 0.05) and diastolic (p < 0.05) BP, total
cholesterol (p < 0.001), LDL-c (p < 0.001), non HDL-c (p <
0.001), triglycerides (p < 0.05), RLP-c (p < 0.01), plasma
glucose (p < 0.05), insulin (p < 0.01), HOMA index (p <
0.01) and HGF (p < 0.05) were significantly decreased. In
contrast, HDL-c (p < 0.001) was significantly increased.
Following 24 weeks of combined therapy, BMI (p < 0.05),
waist circumference (p < 0.01), total cholesterol (p < 0.05),
LDL-c (p < 0.05), non HDL-c (p < 0.01), triglycerides (p <
0.001) and RLP-c (p < 0.001) were significantly decreased.















Total cholesterol (mg/dl) 237.9 ± 35.9 2
LDL-cholesterol (mg/dl) 151.3 ± 28.6 1
HDL-cholesterol (mg/dl) 51.9 ± 9.9
Non HDL-cholesterol (mg/dl) 184.9 ± 31.7 1
Triglycerides+ (mg/dl) 157.5
RLP-cholesterol+ (mg/dl) 6.3
Free fatty acid+ (mEq/l) 435.9





HGF (ng/ml) 0.33 ± 0.07
Adiponectine (μg/ml)+ 2.51
EPA/AA+ 0.29
*: p < 0.05, **: p < 0.01, ***: p < 0.001.
Data are means (SD), geometric mean and range. *: These variables are shown in th
Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model asse
arachidonic acid.Discussion
Twenty-four weeks of ezetimibe treatment ameliorated
not only atherogenic lipid profiles but also anthropomet-
ric factors, insulin resistance and biomarkers such as
HGF. To the best of our knowledge, this is the first re-
port to show that ezetimibe treatment reduced HGF
levels in obese patients with hypercholesterolemia.
Although many studies [3-10] have reported that ezeti-
mibe treatment ameliorated atherogenic lipid profiles, very
few [22,23] have referred to anthropometric data. One re-
port from Japan [22] found no significant differences in
body weight and BMI after ezetimibe treatment. Other
Japanese investigators [24] also suggested that there were
no significant changes in metabolic markers including
BMI and waist circumference before and after ezetimibe
treatment. Although Yagi S, et al. [23] demonstrated that
ezetimibe treatment significantly reduced body weight,
BMI, waist circumference and BP, they did not discuss the
reason. Our data were consistent with theirs in large part.therapy and combined therapy
(n = 71) Combined
therapy
(n = 20)
Post 6M Pre Post 6M
28.0 ± 3.8 27.2 ± 2.0 25.9 ± 1.6*
92.8 ± 8.6*** 91.0 ± 5.6 88.3 ± 5.3**
128.8 ± 13.2* 125.6 ± 13.8 121.8 ± 11.2
75.9 ± 10.6* 71.7 ± 8.2 69.5 ± 7.7
12.0 ± 33.0*** 224.7 ± 27.8 192.2 ± 36.1*
32.4 ± 28.6*** 132.1 ± 26.8 107.8 ± 30.5*
55.1 ± 9.4*** 50.8 ± 11.9 53.3 ± 11.5***









0.31 ± 0.04* 0.31 ± 0.03 0.30 ± 0.02
2.56 2.49 2.47
0.28 0.39 0.40
e original scale after analysis using log (natural)-transformed values.
ssment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to
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duced visceral fat as assessed by abdominal computed
tomography [25]. Our data and others [23-25] suggested
that ezetimibe may play a unique role in the treatment of
metabolic syndrome. The present study revealed that eze-
timibe treatment also ameliorated insulin resistance in
addition to lipid profiles. In one experimental study, ezeti-
mibe was shown to improve insulin resistance in Zucker
fatty rats, a model of obesity [26].
We confirmed that ezetimibe improves HOMA index
as a marker of insulin resistance. Dagli N, et al. [27] re-
ported that low-dose statin (pravastatin) and ezetimibe
combination therapy improved insulin resistance mark-
edly better than high-dose pravastatin monotherapy.
This suggested that combined antilipidemic therapy
may be a more favorable treatment alternative in high-risk
dyslipidemic patients. Hiramitsu S, et al. [24] also demon-
strated that ezetimibe significantly reduced the fasting insu-
lin level (−12.8% reduction) and glycosylated hemoglobin
A1c [HbA1c] (−3.4% reduction). However, Kikuchi K, et al.
[28] reported that ezetimibe restored the postprandial dys-
regulation of lipid but did not affect glucose metabolism in
a double-blind randomized crossover trial.
Interestingly, ezetimibe monotherapy was more effective
than combined therapy in reducing insulin and HOMA
index in this study. These results may be consistent with
our recent report [29].
We have shown that HGF levels as well as RLP-c were
significantly reduced by twenty-four weeks of ezetimibe
treatment. Our colleagues [16] demonstrated that HGF
levels were significantly and strongly associated with meta-
bolic syndrome. HGF is one of the adipocytokines. A report
[30] described the relationship between obesity and serum
HGF levels. It may be feasible to consider that the elevated
HGF levels in obese subjects may be due to fatty liver sec-
ondary to obesity. It is interesting to note that results of the
present study using ezetimibe only (n = 83) are consistent
with a previous report [13]. Taken together, candidate sub-
jects suitable for ezetimibe monotherapy may have multiple
syndromes with underlying insulin resistance.
A limitation of our study is that it was an observa-
tional study without a control group. This study design
did not allow us to evaluate the impact of ezetimibe on
insulin resistance over time. In this study population, we
also recommended standard diet and exercise therapies.
To exclude the effects of the standard diet and exercise
therapies, we examined additional data from another co-
hort. We enrolled 60 subjects, who received health
check-up examinations in 2001 and 2003 in Uku town
in Japan, who took no medicine, and who were recom-
mended standard diet and exercise therapies. Their
HOMA-IR was 1.21 ± 0.84 at baseline in 2001 and 1.31 ±
0.87 at 2-year follow-up in 2003. This group showed no
significant change in insulin resistance (p = 0.272),suggesting that standard diet and exercise therapies
have no significant effects on insulin resistance. Second,
this study was conducted in Japan, where the incidence
of obesity is low compared with Caucasians. A final
limitation is that the number of participants and the
follow-up period may have been insufficient to fully
elucidate the role of ezetimibe. Nevertheless, the pleio-
tropic effects of the ezetimibe treatment were striking
and deserve further investigation. Additional studies of
ezetimibe with a large sample size including predictive
measures of major atherosclerotic diseases are needed.
Conclusions
In conclusion, ezetimibe ameliorated not only athero-
genic lipid profiles but also anthropometric factors,
insulin resistance and biomarkers such as HGF. Ezeti-




This study was approved by the Institutional Review Board
of Community Medicine, Kurume University School of
Medicine, as well as by the ethics committee of Kurume
University. All subjects participated in the study after
making signed informed consents.
Study population and data collection
All outpatients aged over 20 years with obesity (BMI ≥
25kg/m2) and hypercholesterolemia (LDL-c ≥ 120mg/dl)
were registered in this study at Kurume University Hospital
or nearby clinics during 2011 and 2012. After excluding 10
subjects (7 who dropped out and 3 with missing data), 91
patients (39 males and 52 females) were analyzed.
The study was named ERASE METS (Effects on Re-
gression of AtheroSclerotic risks by Ezetimibe for the pa-
tients with METabolic Syndrome) by one of the study
investigators (T.H.). The enrolled subjects were treated
with 10 mg ezetimibe once a day for 24 weeks and were
evaluated at 12 and 24 weeks. We divided the patients
into two groups, one without anti-dyslipidemic agents
(ezetimibe monotherapy, n = 71) and the other with a
statin (combined therapy, n = 20). Standard diet and ex-
ercise therapy for dyslipidemia were recommended dur-
ing the study. Height was measured with shoes on and
weight was measured with the patients in their ordinary
clothing. BMI was calculated as weight (kilograms) di-
vided by the square of height (square meters) as an
index of obesity. In Japan, obesity is defined as BMI over
25kg/m2. Waist circumference was measured at the level
of the umbilicus in the standing position. BP was mea-
sured in the supine position twice at 3-min intervals
using an upright standard sphygmomanometer. Vigor-
ous physical activity and smoking were avoided for at
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with the fifth-phase diastolic pressure was used for ana-
lysis. Blood was drawn from the antecubital vein in the
morning after a 12-hour fast for determinations of lipids
profiles [total cholesterol, LDL-c, triglycerides, HDL-c,
non-HDL-c and RLP-c], free fatty acid (FFA), fasting
plasma glucose (FPG), fasting immune-reactive insulin
(IRI), high-sensitivity C-reactive protein (hs-CRP), aldos-
terone, HGF, adiponectine and EPA/AA. Fasting blood
samples were centrifuged within 1 hour after collection.
The serum levels of total cholesterol, LDL-c, triglycerides,
HDL-c and non-HDL-c, FFA, FPG and IRI were measured
using standard laboratory methods. Serum RLP-c was
measured by immune-separation technique [31] (using an
immune-affinity gel containing monoclonal antibodies to
human apolipoprotein [apo] B-100 and apo A-1). HOMA
index was calculated as FPG (mg/dL) × fasting IRI (μU/
mL)/405 and used as a marker of insulin resistance [32].
Hs-CRP was measured as an inflammatory marker. Plasma
aldosterone was measured in the morning by radio-
immunoassay (RIA), and samples were taken after the sub-
jects had remained in a sitting position for 10 minutes [14].
Plasma HGF levels were measured by the enzyme-linked
immunosorbent assay (ELISA) [33]. Serum adiponectin
concentrations were measured by radioimmunoassay
[18]. Measurement of serum EPA/AA levels were out-
sourced to SRL (Fukuoka, Japan) [20]. All of the blood
tests except for HGF, adiponectin and EPA/AA were mea-
sured in a commercially available laboratory (The Kyodo
Igaku Laboratory, Fukuoka, Japan).
Statistical analysis
Results are presented as the mean ± standard devi-
ation. Variables that were not normally distributed
and/or displayed homogeneity of variances were ana-
lyzed by Mann–Whitney test for independent samples.
Normally distributed variables were analyzed using a
paired t test. The p-values < 0.05 were considered statisti-
cally significant. All statistical analyses were performed
using SAS version 9.3 (SAS Inc., Cary, NC, USA).
Abbreviations
LDL-c: Low-density lipoprotein cholesterol; BMI: Body mass index; HDL: High-
density lipoprotein; RLP-c: Remnant-like particle cholesterol; HGF: Hepatocyte
growth factor; MetS: Metabolic syndrome; EPA: Eicosapentaenoic acid;
AA: Arachidonic acid; BP: Blood pressure; HOMA: Homeostasis model
assessment; HbA1c: Glycosylated hemoglobin A1c; FFA: Free fatty acid;
FPG: Fasting plasma glucose; IRI: Immune-reactive insulin; Hs-CRP: High-
sensitivity C-reactive protein; RIA: Radioimmunoassay; ELISA: Enzyme-linked
immunosorbent assay.
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